Topical regional neuro affective therapy with cannabinoid combination products

1. A method of treating a disease state or condition in human, comprising topically applying onto the surface of the skin in an area extending from behind one ear to the other ear of the mammal and below the hairline at the back of the neck of a human patient administering a unit dose of a cannabinoid drug(s) and a second therapeutically active drug in therapeutically effective amounts formulated in a mousse, cream, gel or ointment that allows for the drug to be immediately absorbable and available for the free nerve endings of the trigeminal nervous system which reside under the skin surface to treat the disease state or condition, to provide regional neuro-affective therapy to the human patient.

2. The method of claim 1 , wherein the cannabinoid drug(s) and the second therapeutically active drug are administered such that they are absorbed in an area of the skin where the afferent components of trigeminal nerve system, cervical sympathetic nerves, and vagus nerve are located.

3. The method of claim 1 , wherein the cannabinoid drug(s) comprise a mixture of pharmaceutically acceptable cannabinoids, such that the mixture provides substantially no psychoactive effect or no psychoactive effect.

4. The method of claim 1 , wherein the cannabinoid drug(s) comprises at least about 80% cannabidiol.

5. The method of claim 1 , wherein the topical pharmaceutical formulation comprises a pharmaceutically acceptable aqueous based carrier.

6. The method of claim 5 , wherein the cannabinoid drug(s) in the pharmaceutical formulation comprises at least about 80% cannabidiol.

7. The method of claim 1 , wherein the condition is diabetic peripheral neuropathy and the second therapeutically active drug is 4-aminopyridine.

8. The method of claim 1 , wherein the condition is selected from the group consisting of benign essential/familial tremor, tremor related to MS, chronic encepahalopathies, congenital CNS degeneration conditions/cerebral palsy, cerebellar degeneration syndromes, and spasticity conditions, and a peripheral neuropathic condition and the second therapeutically active drug is 4-aminopyridine.

9. The method of claim 1 , wherein the condition is spasticity and/or spasms and the second therapeutically active drug is 4-aminopyridine.

10. The method of claim 1 , further comprising a third therapeutically active drug which is a skeletal muscle relaxant.

11. The method of claim 10 , wherein the skeletal muscle relaxant is tizanidine.

12. The method of claim 1 , wherein the cannabinoid drug(s) comprises cannabidiol.

13. The method of claim 6 , wherein the aqueous based pharmaceutically acceptable carrier comprises ethoxydiglycol, water, glycerin, C 12-15 alkyl benzoate, glyceryl stearate, dimethicone, cetearyl alcohol, cetearyl glucoside, polyacrylamide, cetyl alcohol, magnesium aluminum silicate, xanthan gum, aloe vera (aloe barbadensis), tocopheryl acetate (vitamin E acetate), prunus amygadalus amara (bitter almond) kernel oil, Vitis vinifera (grape) seed extract, Triticum vulgare (wheat) germ oil, retinyl palmitate (vitamin A palmitate), ascorbyl palmitate (vitamin C palmitate), pro-lipo multi-emulsion liposomic system, tetrasodium EDTA, phenoxyethanol, and sodium hydroxymethylglycinate.

14. The method of claim 4 , wherein cannabidiol is incorporated into the pharmaceutically acceptable carrier from a CBD-oil.

15. The method of claim 4 , wherein cannabidiol incorporated into the pharmaceutically acceptable carrier is a purified crystalline CBD.

16. The method of claim 1 , wherein the unit dose comprises from about 3 mg to about 50 mg cannabidiol.

17. The method of claim 4 , wherein the unit dose comprises from about 3 mg to about 50 mg cannabidiol.

18. The method of claim 7 , wherein the unit doses comprises from about 1 mg to about 40 mg of 4-aminopyridine.

19. The method of claim 7 , wherein the unit doses comprises from about 2 mg to about 10 mg 4-aminopyridine.